**Name of Journal: *World Journal of Cardiology***

**ESPS Manuscript Number: 30206**

**Manuscript Type: Minireviews**

**Empirical anticoagulation for patients in sinus rhythm at high risk of ischaemic stroke: A review of current literature**

Battipaglia I *et al*.Anticoagulation for high-risk stroke patients

**Irma Battipaglia, James O’Neill, Andrew J Hogarth, Muzahir H Tayebjee**

**Irma Battipaglia,** Department of Cardiovascular Diseases, Catholic University of the Sacred Heart "A. Gemelli" Hospital, 00168 Rome, Italy

**James O’Neill, Andrew J Hogarth, Muzahir H Tayebjee,** Department of Cardiology, Leeds General Infirmary, Leeds LS1 3EX, United Kingdom

**Author contributions:** Battipaglia I wrote the initial manuscript; O’Neill J revised the manuscript, added additional material and designed Table 1; Hogarth AJ and Tayebjee MH devised the concept for the manuscript, advised on appropriate references and reviewed the manuscript prior to submission.

**Conflict-of-interest statement:** O’Neill J has received a fellowship from St. Jude Medical. Tayebjee MH has received research/travel grants from St. Jude Medical, Biosense Webster, Medtronic and Boehringer Ingelheim.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to:** **Dr. Muzahir H Tayebjee, MB ChB (Hons), MRCP, MD,** Department of Cardiology, Leeds General Infirmary, Great George Street, Leeds LS1 3EX, United Kingdom. mhtayebjee@hotmail.com

**Telephone:** +44-113-3926619

**Fax:** +44-113-3923981

**Received:** September 19, 2016

**Peer-review started:** September 23, 2016

**First decision:** November 21, 2016

**Revised:** March 9, 2017

**Accepted:** March 21, 2017

**Article in press:**

**Published online:**

# Abstract

Ischaemic stroke is one of the commonest causes of morbidity and mortality worldwide and around a fifth of events can be attributed to a cardioembolic source. This is typically due to atrial fibrillation (AF), the most common sustained cardiac arrhythmia. However, AF can, at times, be difficult to detect due to a relative lack of symptoms and the fact that it can be paroxysmal in nature. Studies have shown that diagnosis of AF improves as the length of cardiac monitoring increases. However, prolonged cardiac monitoring is not a cost-effective way of diagnosing AF. Therefore, an alternative approach may be to empirically anticoagulate individuals who are at high risk of stroke. This article summarises current evidence surrounding stroke risk prediction, the use of anticoagulation in the secondary prevention of stroke and its use in the primary prevention of stroke in high risk groups with the aim of determining whether empirical anticoagulation is a safe and effective strategy.

**Key words:** Anticoagulation; Ischaemic stroke; Atrial fibrillation; CHA2DS2VASc; CHADS-2; Heart failure; Coronary artery disease; Peripheral arterial disease

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** This is a contemporary review exploring issues related to the risk of stroke and use of anticoagulation in patients who are in sinus rhythm (SR). It examines the prediction of stroke in patients without known atrial fibrillation (AF), the identification of AF in patients following stroke and the use of anticoagulation in post-stroke patients seemingly in SR or those at high-risk of stroke. The main findings are: (1) prolonged cardiac monitoring increases the rate of AF diagnosis but is not cost-effective; (2) current risk stratification schemes such as CHA2DS2VASc can identify those in sinus rhythm who are at risk of stroke; and (3) further research is required to determine whether individuals at high-risk of stroke would benefit from anticoagulation.

Battipaglia I, O’Neill J, Hogarth AJ, Tayebjee MH. Empirical anticoagulation for patients in sinus rhythm at high risk of ischaemic stroke: A review of current literature. *World J Cardiol* 2017; In press

# INTRODUCTION

Ischaemic stroke is a leading cause of morbidity and mortality worldwide[1] and, following a first event, around a quarter of patients will go on to have a recurrent stroke[2,3]. Atrial fibrillation (AF), a common cause of stroke, is the most common sustained cardiac arrhythmia with an estimated prevalence approximately 3% in adults aged 20 years or older[4], a figure that is expected to double over the next 50 years[5]. This arrhythmia carries a five-fold risk of stroke and patients who experience an AF-related stroke often suffer the most severe forms of the condition[6].

Risk scores such as CHADS-2 and, more recently, CHA2DS2VASc have been developed in order to identify those patients with AF and an increased risk of stroke who would potentially benefit from anticoagulation. However, these risk scores are currently used only in patients with a confirmed diagnosis of AF, a condition which is underdiagnosed due to the fact it can be asymptomatic and paroxysmal. Therefore, given that 45% of all AF-related strokes occur in patients with previously undetected AF[7], many more patients could potentially benefit from empirical anticoagulation therapy and there may be a role for using these risk scores in patients without known AF but with risk factors for developing stroke.

In view of the fact that AF can be difficult to detect, a number of studies have attempted to determine whether it is appropriate to give empirical anticoagulation to patients in sinus rhythm (SR) with risk factors for stroke. This article aims to summarise these studies and determine whether there are clinically relevant scenarios where anticoagulating patients in SR may be appropriate to reduce their risk of stroke.

# LITERATURE SEARCH AND METHOD

A Medline and Embase search was performed in August 2016 using the following terms: *CHADS-2, CHA2DS2VASc, anticoagulation, vitamin K antagonist, warfarin, Coumadin, novel oral anticoagulant, direct oral anticoagulant, apixaban, eliquis, dabigatran, pradaxa, rivaroxaban, xarelto, edoxaban, lixiana, sinus rhythm, non-atrial fibrillation, normal heart rhythm, “without atrial fibrillation”, stroke, cerebrovascular accident, cerebrovascular event, TIA, mini-stroke, heart failure, cardiac failure, left ventricular failure, left ventricular impairment, left ventricular dysfunction, impaired ventricle, coronary artery disease, coronary heart disease, myocardial ischaemia, myocardial infarction, acute coronary syndrome, peripheral arterial disease* and *peripheral vascular disease*.

# STROKE RISK PREDICTION IN A GENERAL POPULATION WITHOUT AF

In patients without known AF, risk assessment tools currently focus on overall cardiovascular risk rather than determining their specific risk of stroke. However, could risk scores such as CHADS-2 and CHA2DS2VASc be used within this patient group to determine their cerebrovascular event risk?

An analysis of the Chin-Shan Community Cohort Study tested a number of risk stratification schemes which are currently used to predict thromboembolic risk in AF, including CHADS-2 and CHA2DS2VASc, in a Chinese population without known AF[8]. This showed a modest predictive value of these risk stratification schemes in predicting stroke in non-AF patients with a C-statistic value ranging from 0.658 to 0.728, values which were broadly similar to those seen in an exploratory analysis of patients with AF within the same community.

Similar results were found in a meta-analysis performed by Santos et al who examined the use of the CHADS-2 score at predicting cerebrovascular events[9]. They found that CHADS-2 was able to identify patients at risk of stroke, regardless of whether AF was present or not.

More recently, Saliba et al assessed the performance of CHADS-2 and CHA2DS2VASc within a large Israeli population over a three year follow-up period[10]. In individuals without AF, the C-statistic values were 0.718 and 0.714 for CHADS-2 and CHA2DS2VASc respectively and in individuals with AF, the C-statistic values were 0.606 and 0.610 respectively. The authors concluded that these risk tools had a relatively high performance at predicting thromboembolism in patients without AF.

In all of these studies, the results suggest that current risk stratification schemes used in AF patients to predict thromboembolism could also be used in patients without AF as a screening tool to predict their risk of stroke. It remains unclear, however, as to whether anticoagulating these patients is a superior strategy to giving antiplatelet therapy.

# SECONDARY PREVENTION OF ISCHAEMIC STROKE/TIA

Around a fifth of ischaemic strokes are cardioembolic in origin[11] and these patients typically receive oral anticoagulants to reduce their risk of future events. However, around a third of ischaemic strokes are termed cryptogenic[12], or without an attributable cause despite extensive work-up. The majority of these cases are likely to have an embolic mechanism and a significant proportion are likely to be related to undiagnosed AF.

Ziegler *et al*[13] analysed data from patients at risk of thromboembolism (stroke/TIA) who had implantable cardiac devices capable of recording atrial arrhythmias. They identified newly detected episodes of atrial fibrillation/tachycardia in 28% of patients over a 1 year follow-up period.

Multiple studies have shown that the yield of detecting AF increases as the length of ambulatory monitoring increases (see Table 1)[14-17]. A systematic review and meta-analysis performed by Dussault et al assessed the relationship between the duration of ECG monitoring and the incidence of AF detection in patients who had suffered a cerebrovascular event, using data from 31 studies[18]. They found that extending monitoring from 24 h to 30 d improved AF detection from 4.38% to 15.2% and if this monitoring was extended out to 180 d, detection rates increased to 29.15%.

Studies have also shown that in patients with implantable electronic devices, asymptomatic episodes of AF can be associated with an increased risk of thromboembolic events[19-25], with a hazard ratio ranging from 2.2 to 9.4[26]. The length of each episode that is required to increase overall stroke risk varies in these studies, from a minimum of 5 min in the Ancillary MOde Selection Trial (MOST)[19] to a maximum of 24 h in the Italian AT500 Registry[20]. At present, the episode duration and burden of asymptomatic AF that best predict future thromboembolic events are still matters of debate and need to be addressed by future studies.

A more recent systematic review performed by the Canadian Agency for Drugs and Technologies in Health (CADTH) examined not only the clinical effectiveness of cardiac monitoring in patients who had recently experienced a stroke or TIA, but also the cost effectiveness[27]. They showed that there was a substantial increase in the detection of AF when monitoring was performed for more than 24 h. Monitoring beyond 30 d increased this detection further although these improvements were modest. From an economic point of view, they concluded that in patients who were admitted with a cerebrovascular event and did not receive in-patient continuous cardiac monitoring, 7 d cardiac monitoring was likely to identify significantly more cases of AF compared with current 24 hour monitoring, with an acceptable increase in cost [CAN$ 50000-80000/QALY (£ 28000-46000/QALY) gained]. Cost-effectiveness could be improved further by targeting stroke survivors who were relatively healthy and in whom there was a higher suspicion of underlying AF. However, they also concluded that extending monitoring beyond 7 d was unlikely to be cost-effective [> CAN$ 85000/QALY (>£ 49000/QALY) gained].

Current guidance continues to recommend long-term cardiac monitoring in patients who have a stroke with an undiagnosed cause with the AHA/ACC/HRS specifying at least 30 d. In view of the fact that this may not be cost-effective, would it be more appropriate to use current risk stratification schemes to identify those patients who may be at risk of further cerebrovascular events?

A trial by Ntaios et al examined whether CHADS-2 and CHA2DS2VASc scores could be used to predict long-term outcomes in non-AF stroke patients[28]. They divided patients into low, intermediate or high risk sub-groups, dependent upon their pre-stroke CHADS-2 and CHA2DS2VASc score. In both the CHADS-2 and CHA2DS2VASc sub-groups, they found that there were significant differences in stroke recurrence, cardiovascular events and 5-year mortality. They also demonstrated that compared with the low-risk sub-group, patients in the high-risk sub-group had a higher risk of stroke recurrence [CHADS-2, hazard ratio (HR): 1.71; CHA2DS2VASc, HR: 2.93]. These results suggest that current clinical risk scores can be used to predict future events in patients who have had a stroke or TIA.

To improve the accuracy of these risks scores in post-stroke patients further, modification of certain variables may be helpful. Thijs et al assessed patients who had suffered a cryptogenic stroke or TIA and had an insertable cardiac monitor to determine whether there were specific factors which could predict the development of AF in this population[29]. Following multivariate analysis, they found that increasing age [HR per decade 1.9 (1.3-2.8), *P =* 0.0009] and PR interval prolongation [HR per 10 ms: 1.3 (1.2-1.4), *P <* 0.0001] were independently associated with an increased incidence of AF. Therefore, in non-AF stroke/TIA patients, the addition of PR interval duration and placing further emphasis on age may help improve the accuracy of current risk scores.

Nevertheless, despite the fact that CHADS-2 and CHA2DS2VASc may help to predict future events in non-AF stroke/TIA patients, more evidence is required to determine whether those within an intermediate or high-risk group should be offered anticoagulation.

# PRIMARY PREVENTION OF ISCHAEMIC STROKE/TIA IN SPECIFIC GROUPS

# *Heart failure*

It has long been established that heart failure (HF) is associated with an increased risk of thromboembolism and in particular, stroke. A systematic review performed by Witt et al analysed stroke rates in heart failure patients and found the risk of stroke to be 1.8% in the first year of HF diagnosis, rising to 4.7% at 5 years[30]. Multiple studies have attempted to clarify whether HF patients in SR would benefit from anticoagulant therapy. Initial trials suffered from poor recruitment and underpowered results and so it is not surprising that they failed to demonstrate an overall benefit of anticoagulation in this population[31-33]. One of these studies, the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial, did however show a significant reduction in non-fatal ischaemic strokes in patients on warfarin compared with aspirin or clopidogrel (*P <* 0.01)[33]. This was at the expense of a higher rate of major bleeding events.

More recently, the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial compared warfarin and aspirin in patients with HF in SR, using the primary endpoints of ischaemic stroke, intracerebral haemorrhage or death from any cause[34]. Although there was no overall difference in the combined primary endpoints between the two treatments (*P =* 0.4), warfarin was associated with a significant reduction in the rate of ischaemic stroke (2.5% *vs* 4.7%, *P =* 0.005) without a significant difference in the rate of intracerebral or intracranial haemorrhage (*P =* 0.82). Once again, the rate of major bleeding was higher (warfarin 5.8% *vs* aspirin 2.7%, *P* <0.001).

One limitation of the WARCEF study was the time in therapeutic range (TTR) among patients in the warfarin group which was relatively low at 63% (high-quality warfarin treatment is defined as a TTR >70%[35]). Low TTRs are strongly associated with adverse outcomes such as major haemorrhage and thromboembolic events[35]. The higher bleeding risk with warfarin may, in part, be related to this low TTR. One solution to this could be use of direct oral anticoagulants (DOACs) which, in the absence of compliance issues, provide a much more consistent level of therapeutic anticoagulation. DOACs have already been shown to be non-inferior, and in some cases, superior to warfarin with respect to stroke and major bleeding risk reduction[36-39]. Further research exploring the use of DOACs in HF patients is needed to determine whether they can reduce thromboembolic risk without significantly increasing bleeding risk.

In terms of estimating stroke risk within HF patients without AF, current clinical risk scores have been assessed. A recent prospective cohort study investigated whether CHA2DS2VASc could be used to predict the risk of ischaemic stroke in HF patients without AF[40]. It performed moderately at predicting ischaemic stroke at 1- and 5-year follow-up (C-statistics 0.67 and 0.69 respectively) and performed well at identifying those at low risk of ischaemic stroke with a negative predictive value of 92%. Additionally, the authors found that those with a CHA2DS2-VASc score of ≥ 2 had a stroke risk of > 1% per year. To put this into context, patients with AF are typically offered anticoagulation once their annual stroke risk exceeds 1%. This would suggest that the CHA2DS2-VASc score may have a use in identifying those HF patients without AF who at risk of stroke. Whether these patients would gain benefit from anticoagulation remains to be seen and clinical trials are needed to clarify this.

# *Coronary artery disease*

Coronary artery disease (CAD) has been identified as an independent risk factor for stroke[41] and co-existent vascular disease, such as coronary or peripheral artery disease, is present in around 40% of stroke patients[42]. Studies have previously examined the addition of warfarin to antiplatelet therapy in patients with acute coronary syndrome (ACS). These were performed in an era before the widespread use of dual antiplatelet therapy. A meta-analysis of the studies found that the addition of warfarin led to reduction in major adverse cardiovascular events (MACE: death, non-fatal MI, non-fatal ischaemic stroke; [OR 0.73 (0.63–0.84), *P <* 0.0001]) but this was at the expense of an increased risk of major bleeding [OR 2.32 (1.63-3.29), *P <* 0.00001][43]. As a result, anticoagulation is not routinely given to patients following ACS. However, a proportion of these patients will be at significant risk of thromboembolic events and if a clinical risk score could accurately identify this sub-group, they might well benefit from anticoagulation.

A prospective registry study by Mitchell et al assessed the accuracy of CHADS-2 and CHA2DS2VASc at predicting cerebrovascular events in non-AF patients who had suffered an ACS[44]. They found that the incidence of stroke increased with increases in each risk score and that a CHADS-2 score ≥ 3 or a CHA2DS2VASc score ≥ 4 was associated with an annual stroke incidence of ≥ 1%. Both CHADS-2 and CHA2DS2VASc performed moderately at predicting ischaemic stroke (C-Statistics (0.68 and 0.71 respectively).

Similar results were found in a prospective cohort study which assessed the accuracy of CHADS-2 at predicting cerebrovascular events in non-AF patients who had stable CAD[45]. Those with a CHADS-2 score of 2-3 had a 2.7 times higher rate of stroke and those with a CHADS-2 score of 4-6 had a 4.6 times higher rate of stroke. They concluded that stable CAD patients with a CHADS-2 score of 5-6 had a comparable stroke rate to AF patients with a CHADS-2 score of 2-3, the level at which anticoagulation is felt to be beneficial.

In both of these studies, cerebrovascular events occurred despite antiplatelet therapy. They indicate that in patients with CAD, high CHADS-2 or CHA2DS2VASc scores can predict those at risk of stroke or TIA. These patients may therefore benefit from the addition of anticoagulation and further studies are required to clarify this.

# *Peripheral arterial disease*

The presence of peripheral arterial disease (PAD) is a significant predictor of stroke and in one study was found to be present in 14.4% of major ischaemic strokes and 8.9% of minor ischaemic strokes[46]. Warfarin has also been evaluated for the use in this patient group. A meta-analysis which assessed the use of anticoagulation in PAD patients provided inconclusive results[47] and led to the development of the Warfarin Antiplatelet Vascular Evaluation (WAVE) Trial[48]. This compared oral anticoagulation plus antiplatelet therapy versus antiplatelet therapy alone. They found no significant difference in MACE events (relative risk: 0.92; 95%CI: 0.73 to 1.16; *P* = 0.48). However, those receiving combination therapy had a significantly higher rate of major bleeding rate (4.0%), compared with in those receiving antiplatelet monotherapy (1.2%). There is some evidence that patients undergoing vein graft bypass surgery gain benefit from warfarin monotherapy[49] and this is the only sub-group of PAD patients in which anticoagulation is currently indicated.

To date, there is only one trial which has examined the use of clinical risk scores to predict thromboembolic events in patients with PAD. Yang et al assessed the accuracy of CHADS-2 and CHA2DS2VASc in predicting 5-year cumulative ischaemic stroke risk in PAD patients[50]. They found that each increase in the risk scores led to an increased stroke risk, and both scores performed well at predicting 5-year cerebrovascular events (C-statistics 0.92 for CHADS-2, 0.862 for CHA2DS2VASc). In multivariate analysis, each increment of the CHADS-2 or CHA2DS2VASc score was associated with around a three-fold increase in stroke risk.

As with CAD, current risk scores appear to be able to identify those PAD patients who are at high-risk of cerebrovascular events and this sub-group may also benefit from anticoagulation therapy. More clinical evidence is required to confirm this.

# CONCLUSION

Cerebrovascular disease remains one of the leading causes of death throughout the world. Those that survive are commonly left with serious long-term disability and are at an increased risk of recurrent events. AF is a common cause of stroke/TIA but because the arrhythmia can be paroxysmal and asymptomatic, it remains a challenge to detect. Long-term ambulatory monitoring has not been shown to be a cost-effective way of diagnosing the arrhythmia. Additionally, the duration of AF which represents an increased risk of thromboembolism is still to be determined.

An alternative strategy is to use current risk stratification schemes such as CHADS-2 or CHA2DS2VASc. There is evidence to suggest that these scores can identify those at significant risk of thromboembolic events, not only in the general population but more specifically in those that have suffered a cerebrovascular event or have co-existent HF, CAD or PAD.

At present, it remains unclear as to the most appropriate way of treating these high-risk patients once they have been identified. With the dawn of DOACs, which can provide a more steady-state of anticoagulation and potentially have a better bleeding profile, there are now therapeutic options which may benefit high-risk groups. Future trials should use risk scores to identify high-risk groups in a variety of clinical settings to determine whether anticoagulation therapy can reduce the burden of cerebrovascular disease.

# REFERENCES

1. **Lopez AD**, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. *Lancet* 2006; **367**: 1747-1757 [PMID: 16731270 DOI: 10.1016/S0140-6736(06)68770-9]
2. **Lee S**, Shafe AC, Cowie MR. UK stroke incidence, mortality and cardiovascular risk management 1999-2008: time-trend analysis from the General Practice Research Database. *BMJ Open* 2011; **1**: e000269 [PMID: 22021893 DOI: 10.1136/bmjopen-2011-000269]
3. **Kernan WN**, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, Fang MC, Fisher M, Furie KL, Heck DV, Johnston SC, Kasner SE, Kittner SJ, Mitchell PH, Rich MW, Richardson D, Schwamm LH, Wilson JA. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2014; **45**: 2160-2236 [PMID: 24788967 DOI: 10.1161/STR.0000000000000024]
4. **Kirchhof P**, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J* 2016; **37**: 2893-2962 [PMID: 27567408 DOI: 10.1093/eurheartj/ehw210]
5. **Go AS**, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. *JAMA* 2001; **285**: 2370-2375 [PMID: 11343485 DOI: 10.1001/jama.285.18.2370]
6. **McGrath ER**, Kapral MK, Fang J, Eikelboom JW, Conghaile Aó, Canavan M, O'Donnell MJ. Association of atrial fibrillation with mortality and disability after ischemic stroke. *Neurology* 2013; **81**: 825-832 [PMID: 23902702 DOI: 10.1212/WNL.0b013e3182a2cc15]
7. **Pisters R**, van Oostenbrugge RJ, Knottnerus IL, de Vos CB, Boreas A, Lodder J, Prins MH, Crijns HJ, Tieleman RG. The likelihood of decreasing strokes in atrial fibrillation patients by strict application of guidelines. *Europace* 2010; **12**: 779-784 [PMID: 20348143 DOI: 10.1093/europace/euq080]
8. **Lip GY**, Lin HJ, Chien KL, Hsu HC, Su TC, Chen MF, Lee YT. Comparative assessment of published atrial fibrillation stroke risk stratification schemes for predicting stroke, in a non-atrial fibrillation population: the Chin-Shan Community Cohort Study. *Int J Cardiol* 2013; **168**: 414-419 [PMID: 23073283 DOI: 10.1016/j.ijcard.2012.09.148]
9. **Santos C**, Pereira T, Conde J. CHADS2 score in predicting cerebrovascular events: a meta-analysis. *Arq Bras Cardiol* 2013; **100**: 294-301 [PMID: 23598585 DOI: 10.5935/abc.20130068]
10. **Saliba W**, Gronich N, Barnett-Griness O, Rennert G. The role of CHADS2 and CHA2 DS2 -VASc scores in the prediction of stroke in individuals without atrial fibrillation: a population-based study. *J Thromb Haemost* 2016; **14**: 1155-1162 [PMID: 27037960 DOI: 10.1111/jth.13324]
11. **Wessler BS**, Kent DM. Controversies in cardioembolic stroke. *Curr Treat Options Cardiovasc Med* 2015; **17**: 358 [PMID: 25398426 DOI: 10.1007/s11936-014-0358-6]
12. **Li L**, Yiin GS, Geraghty OC, Schulz UG, Kuker W, Mehta Z, Rothwell PM. Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study. *Lancet Neurol* 2015; **14**: 903-913 [PMID: 26227434 DOI: 10.1016/S1474-4422(15)00132-5]
13. **Ziegler PD**, Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Koehler JL, Hilker CE. Incidence of newly detected atrial arrhythmias via implantable devices in patients with a history of thromboembolic events. *Stroke* 2010; **41**: 256-260 [PMID: 20044517 DOI: 10.1161/STROKEAHA.109.571455]
14. **Higgins P**, MacFarlane PW, Dawson J, McInnes GT, Langhorne P, Lees KR. Noninvasive cardiac event monitoring to detect atrial fibrillation after ischemic stroke: a randomized, controlled trial. *Stroke* 2013; **44**: 2525-2531 [PMID: 23899913 DOI: 10.1161/STROKEAHA.113.001927]
15. **Gladstone DJ**, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, Vaid H, O'Donnell M, Laupacis A, Côté R, Sharma M, Blakely JA, Shuaib A, Hachinski V, Coutts SB, Sahlas DJ, Teal P, Yip S, Spence JD, Buck B, Verreault S, Casaubon LK, Penn A, Selchen D, Jin A, Howse D, Mehdiratta M, Boyle K, Aviv R, Kapral MK, Mamdani M. Atrial fibrillation in patients with cryptogenic stroke. *N Engl J Med* 2014; **370**: 2467-2477 [PMID: 24963566 DOI: 10.1056/NEJMoa1311376]
16. **Sanna T**, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, Rymer MM, Thijs V, Rogers T, Beckers F, Lindborg K, Brachmann J. Cryptogenic stroke and underlying atrial fibrillation. *N Engl J Med* 2014; **370**: 2478-2486 [PMID: 24963567 DOI: 10.1056/NEJMoa1313600]
17. **Brachmann J**, Morillo CA, Sanna T, Di Lazzaro V, Diener HC, Bernstein RA, Rymer M, Ziegler PD, Liu S, Passman RS. Uncovering Atrial Fibrillation Beyond Short-Term Monitoring in Cryptogenic Stroke Patients: Three-Year Results From the Cryptogenic Stroke and Underlying Atrial Fibrillation Trial. *Circ Arrhythm Electrophysiol* 2016; **9**: e003333 [PMID: 26763225 DOI: 10.1161/CIRCEP.115.003333]
18. **Dussault C**, Toeg H, Nathan M, Wang ZJ, Roux JF, Secemsky E. Electrocardiographic monitoring for detecting atrial fibrillation after ischemic stroke or transient ischemic attack: systematic review and meta-analysis. *Circ Arrhythm Electrophysiol* 2015; **8**: 263-269 [PMID: 25639643 DOI: 10.1161/CIRCEP.114.002521]
19. **Glotzer TV**, Hellkamp AS, Zimmerman J, Sweeney MO, Yee R, Marinchak R, Cook J, Paraschos A, Love J, Radoslovich G, Lee KL, Lamas GA. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). *Circulation* 2003; **107**: 1614-1619 [PMID: 12668495 DOI: 10.1161/01.CIR.0000057981.70380.45]
20. **Capucci A**, Santini M, Padeletti L, Gulizia M, Botto G, Boriani G, Ricci R, Favale S, Zolezzi F, Di Belardino N, Molon G, Drago F, Villani GQ, Mazzini E, Vimercati M, Grammatico A. Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers. *J Am Coll Cardiol* 2005; **46**: 1913-1920 [PMID: 16286180 DOI: 10.1016/j.jacc.2005.07.044]
21. **Botto GL**, Padeletti L, Santini M, Capucci A, Gulizia M, Zolezzi F, Favale S, Molon G, Ricci R, Biffi M, Russo G, Vimercati M, Corbucci G, Boriani G. Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. *J Cardiovasc Electrophysiol* 2009; **20**: 241-248 [PMID: 19175849 DOI: 10.1111/j.1540-8167.2008.01320.x]
22. **Glotzer TV**, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilker C, Miller C, Qi D, Ziegler PD. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. *Circ Arrhythm Electrophysiol* 2009; **2**: 474-480 [PMID: 19843914 DOI: 10.1161/CIRCEP.109.849638]
23. **Shanmugam N**, Boerdlein A, Proff J, Ong P, Valencia O, Maier SK, Bauer WR, Paul V, Sack S. Detection of atrial high-rate events by continuous home monitoring: clinical significance in the heart failure-cardiac resynchronization therapy population. *Europace* 2012; **14**: 230-237 [PMID: 21933802 DOI: 10.1093/europace/eur293]
24. **Healey JS**, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, Yang S, Bailleul C, Morillo CA, Carlson M, Themeles E, Kaufman ES, Hohnloser SH. Subclinical atrial fibrillation and the risk of stroke. *N Engl J Med* 2012; **366**: 120-129 [PMID: 22236222 DOI: 10.1056/NEJMoa1105575]
25. **Boriani G**, Glotzer TV, Santini M, West TM, De Melis M, Sepsi M, Gasparini M, Lewalter T, Camm JA, Singer DE. Device-detected atrial fibrillation and risk for stroke: an analysis of & gt; 10,000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices). *Eur Heart J* 2014; **35**: 508-516 [PMID: 24334432 DOI: 10.1093/eurheartj/eht491]
26. **Glotzer TV**, Ziegler PD. Cryptogenic stroke: Is silent atrial fibrillation the culprit? *Heart Rhythm* 2015; **12**: 234-241 [PMID: 25285649 DOI: 10.1016/j.hrthm.2014.09.058]
27. **De Angelis G**, Cimon K, Sinclair A, Farrah K, Cairns J, Baranchuk A, Cipriano LE, Akhtar AO, Weeks L, Rader T, Garland S. Monitoring for Atrial Fibrillation in Discharged Stroke and Transient Ischemic Attack Patients: A Clinical and Cost-Effectiveness Analysis and Review of Patient Preferences. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Mar [PMID: 27227190]
28. **Ntaios G**, Lip GY, Makaritsis K, Papavasileiou V, Vemmou A, Koroboki E, Savvari P, Manios E, Milionis H, Vemmos K. CHADS₂, CHA₂S₂DS₂-VASc, and long-term stroke outcome in patients without atrial fibrillation. *Neurology* 2013; **80**: 1009-1017 [PMID: 23408865 DOI: 10.1212/WNL.0b013e318287281b]
29. **Thijs VN**, Brachmann J, Morillo CA, Passman RS, Sanna T, Bernstein RA, Diener HC, Di Lazzaro V, Rymer MM, Hogge L, Rogers TB, Ziegler PD, Assar MD. Predictors for atrial fibrillation detection after cryptogenic stroke: Results from CRYSTAL AF. *Neurology* 2016; **86**: 261-269 [PMID: 26683642 DOI: 10.1212/WNL.0000000000002282]
30. **Witt BJ**, Gami AS, Ballman KV, Brown RD, Meverden RA, Jacobsen SJ, Roger VL. The incidence of ischemic stroke in chronic heart failure: a meta-analysis. *J Card Fail* 2007; **13**: 489-496 [PMID: 17675064 DOI: 10.1016/j.cardfail.2007.01.009]
31. **Cleland JG**, Findlay I, Jafri S, Sutton G, Falk R, Bulpitt C, Prentice C, Ford I, Trainer A, Poole-Wilson PA. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. *Am Heart J* 2004; **148**: 157-164 [PMID: 15215806 DOI: 10.1016/j.ahj.2004.03.010]
32. **Cokkinos DV**, Haralabopoulos GC, Kostis JB, Toutouzas PK. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. *Eur J Heart Fail* 2006; **8**: 428-432 [PMID: 16737850 DOI: 10.1016/j.ejheart.2006.02.012]
33. **Massie BM**, Collins JF, Ammon SE, Armstrong PW, Cleland JG, Ezekowitz M, Jafri SM, Krol WF, O'Connor CM, Schulman KA, Teo K, Warren SR. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. *Circulation* 2009; **119**: 1616-1624 [PMID: 19289640 DOI: 10.1161/CIRCULATIONAHA.108.801753]
34. **Homma S**, Thompson JL, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR, Ammon SE, Graham S, Sacco RL, Mann DL, Mohr JP, Massie BM, Labovitz AJ, Anker SD, Lok DJ, Ponikowski P, Estol CJ, Lip GY, Di Tullio MR, Sanford AR, Mejia V, Gabriel AP, del Valle ML, Buchsbaum R. Warfarin and aspirin in patients with heart failure and sinus rhythm. *N Engl J Med* 2012; **366**: 1859-1869 [PMID: 22551105 DOI: 10.1056/NEJMoa1202299]
35. **De Caterina R**, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Verheugt FW, Weitz JI. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. *Thromb Haemost* 2013; **110**: 1087-1107 [PMID: 24226379 DOI: 10.1160/TH13-06-0443]
36. **Connolly SJ**, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2009; **361**: 1139-1151 [PMID: 19717844 DOI: 10.1056/NEJMoa0905561]
37. **Patel MR**, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med* 2011; **365**: 883-891 [PMID: 21830957 DOI: 10.1056/NEJMoa1009638]
38. **Granger CB**, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L. Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2011; **365**: 981-992 [PMID: 21870978 DOI: 10.1056/NEJMoa1107039]
39. **Giugliano RP**, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM. Edoxaban versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2013; **369**: 2093-2104 [PMID: 24251359 DOI: 10.1056/NEJMoa1310907]
40. **Melgaard L**, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, Lip GY. Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation. *JAMA* 2015; **314**: 1030-1038 [PMID: 26318604 DOI: 10.1001/jama.2015.10725]
41. **Hughes M**, Lip GY. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. *Thromb Haemost* 2008; **99**: 295-304 [PMID: 18278178 DOI: 10.1160/TH07-08-0508]
42. **Bhatt DL**, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, Goto S, Liau CS, Richard AJ, Röther J, Wilson PW. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. *JAMA* 2006; **295**: 180-189 [PMID: 16403930 DOI: 10.1001/jama.295.2.180]
43. **Andreotti F**, Testa L, Biondi-Zoccai GG, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. *Eur Heart J* 2006; **27**: 519-526 [PMID: 16143706 DOI: 10.1093/eurheartj/ehi485]
44. **Mitchell LB**, Southern DA, Galbraith D, Ghali WA, Knudtson M, Wilton SB. Prediction of stroke or TIA in patients without atrial fibrillation using CHADS2 and CHA2DS2-VASc scores. *Heart* 2014; **100**: 1524-1530 [PMID: 24860007 DOI: 10.1136/heartjnl-2013-305303]
45. **Welles CC**, Whooley MA, Na B, Ganz P, Schiller NB, Turakhia MP. The CHADS2 score predicts ischemic stroke in the absence of atrial fibrillation among subjects with coronary heart disease: data from the Heart and Soul Study. *Am Heart J* 2011; **162**: 555-561 [PMID: 21884876 DOI: 10.1016/j.ahj.2011.05.023]
46. **Banerjee A**, Fowkes FG, Rothwell PM. Associations between peripheral artery disease and ischemic stroke: implications for primary and secondary prevention. *Stroke* 2010; **41**: 2102-2107 [PMID: 20689082 DOI: 10.1161/STROKEAHA.110.582627]
47. **WAVE Investigators**. The effects of oral anticoagulants in patients with peripheral arterial disease: rationale, design, and baseline characteristics of the Warfarin and Antiplatelet Vascular Evaluation (WAVE) trial, including a meta-analysis of trials. *Am Heart J* 2006; **151**: 1-9 [PMID: 16368284 DOI: 10.1016/j.ahj.2005.03.021]
48. **Anand S**, Yusuf S, Xie C, Pogue J, Eikelboom J, Budaj A, Sussex B, Liu L, Guzman R, Cina C, Crowell R, Keltai M, Gosselin G. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. *N Engl J Med* 2007; **357**: 217-227 [PMID: 17634457 DOI: 10.1056/NEJMoa065959]
49. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial. *Lancet* 2000; **355**: 346-351 [PMID: 10665553]
50. **Yang YW**, Chen YH, Hsu CC, Lee CC, Kuo YH, Chuang HY, Hsieh TF. CHADS2 Scores as a Predictor of Ischemic Stroke in Patients With Peripheral Artery Disease. *Mayo Clin Proc* 2016; **91**: 45-50 [PMID: 26678007 DOI: 10.1016/j.mayocp.2015.09.021]

**P-Reviewer:** Feher G, Hagemeyer CE **S-Editor:** Kong JX **L-Editor: E-Editor:**

# Table 1 Randomised control trials which show an increased yield of atrial fibrillation detection with extended cardiac monitoring

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Study/Year** | **Design** | **Number of patients** | **Inclusion/exclusion criteria** | **Type of monitoring** | **Outcome** | **Comments** |
| Higgins *et al*[14](2013) | RCT | 100 | Inclusion: Ischaemic stroke within 7 d;Exclusion: History of AF | 7-d event recorder*vs*24-h ECG (control) | Detection of AF: Sustained (> 20 s) and non-sustained (minimum 6 beats) | Sustained AF detected in 18% (control 2%); Non-sustained AF in 44% (control 4%) |
| Gladstone *et al*[15](2014) | RCT | 572 | Inclusion: Cryptogenic stroke,Age ≥ 55 yr;Exclusion: History of AF | 30-d triggered event recorder*vs*24-h ECG (control) | Detection of AF(> 30 s) | AF detected in 16.1% (control 3.2%) |
| Sanna *et al*[16](2014)Brachmann *et al*[17](2016)  | RCT | 441 | Inclusion: Cryptogenic stroke,Age ≥ 40 yr;Exclusion:History of AF (including 24-h ECG) | Insertable cardiac monitor*vs*Standard care (control) | Detection of AF(> 30 s) | At 6 mo, AF detected in 8.9% (control 1.4%)At 12 mo, AF detected in 12.4% (control 2.0%)At 36 mo, AF detected in 30% (control 3.0%) |

AF: Atrial fibrillation; RCT: Randomized controlled trial.